drugset / Trial / NCT02971228
Feasibility Trial Testing the Bionic Pancreas With ZP4207
Phase 2
Completed
13 enrolled
Zealand Pharma
Beta Bionics, Inc. · collabMassachusetts General Hospital · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon\*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus. \*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
Timeline
- Start
- 2016-11
- Primary completion
- 2017-05-24
- Completion
- 2017-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dasiglucagon | Peptide | — | Subcutaneous |
| Subject | Glucagon | Peptide | — | Subcutaneous |
| Background | Insulin Lispro | Protein / enzyme biologic | — | — |